Literature DB >> 16782418

Megakaryocyte-mediated inhibition of osteoclast development.

Melissa A Kacena1, Tracy Nelson2, Mary E Clough2, Sun-Kyeong Lee3, Joseph A Lorenzo3, Caren M Gundberg2, Mark C Horowitz2.   

Abstract

A growing body of evidence indicates that megakaryocytes (MK) or their growth factors play a role in skeletal homeostasis. We previously identified a novel regulatory pathway that controls bone formation, which is mediated by MK. In vivo megakaryocytosis resulted in massive bone formation. The co-culture of MK with osteoblasts (OB) resulted in increased OB proliferation in vitro, by a mechanism that required direct cell-to-cell contact. Here, we examined a second MK-mediated pathway that regulates osteoclast (OC) development. We have begun examining the unique inhibitory effect of MK on OC development. Spleen or bone marrow (BM) cells from C57BL/6 mice, as a source of OC precursors, were cultured with M-CSF and RANKL to induce OC development. MK were prepared by culturing fetal liver cells with thrombopoietin and separating cells into MK and non-MK populations. MK were titrated into spleen cell cultures and OC were identified as tartrate-resistant acid phosphatase-positive giant cells with >3 nuclei. There was a significant, P < 0.001, up to 10-fold reduction in OC formed when MK were added to the spleen cell cultures. We determined that 30% (vol:vol) MK conditioned media (CM) were able to completely block OC development from precursors, whereas 3% MK CM resulted in up to a 10-fold reduction in OC development, P < 0.001. These data indicate that a soluble factor(s) was responsible, at least in part, for the inhibition. We examined MK CM for known inhibitors of OC formation, using ELISAs. IL-4 was undetectable in MK CM, whereas IL-10 and IFN-gamma levels were similar in MK and non-MK CM. TGFbeta-1 levels were increased 2-fold in MK CM compared to control CM but were not responsible for the inhibition in OC development. Although, we found a significant increase in the levels of osteoprotegerin (OPG) in MK CM, antibody neutralization studies, MK derived from OPG-deficient mice, and tandem mass spectrophotometry, all confirm that OPG was not responsible for the MK-mediated inhibition of OC development. Overall, these data suggest that an unidentified factor(s) is present in MK CM that inhibits OC development. These studies indicate that MK can play a dual role in skeletal homeostasis by stimulating OB proliferation and simultaneously inhibiting OC development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782418     DOI: 10.1016/j.bone.2006.05.004

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  37 in total

1.  Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts.

Authors:  Melissa A Kacena; Pierre P Eleniste; Ying-Hua Cheng; Su Huang; Mahesh Shivanna; Tomas E Meijome; Lindsey D Mayo; Angela Bruzzaniti
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

Review 2.  Cell biology of osteoimmunology.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2010-08-16

Review 3.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 4.  Emerging roles for myeloid immune cells in bone metastasis.

Authors:  Massar Alsamraae; Leah M Cook
Journal:  Cancer Metastasis Rev       Date:  2021-04-14       Impact factor: 9.264

5.  Lung megakaryocytes display distinct transcriptional and phenotypic properties.

Authors:  Anthony K Yeung; Carlos Villacorta-Martin; Stephanie Hon; Jason R Rock; George J Murphy
Journal:  Blood Adv       Date:  2020-12-22

6.  Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Authors:  David J Olivos; Marta Alvarez; Ying-Hua Cheng; Richard Adam Hooker; Wendy A Ciovacco; Monique Bethel; Haley McGough; Christopher Yim; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

7.  Association of SMAD2 polymorphisms with bone mineral density in postmenopausal Korean women.

Authors:  B-J Kim; J-Y Hwang; B-G Han; J-Y Lee; J Y Lee; E K Park; S H Lee; Y-E Chung; G S Kim; S-Y Kim; J-M Koh
Journal:  Osteoporos Int       Date:  2010-10-30       Impact factor: 4.507

8.  Aging negatively impacts the ability of megakaryocytes to stimulate osteoblast proliferation and bone mass.

Authors:  Kevin A Maupin; Evan R Himes; Artur P Plett; Hui Lin Chua; Pratibha Singh; Joydeep Ghosh; Safa F Mohamad; Irushi Abeysekera; Alexa Fisher; Carol Sampson; Jung-Min Hong; Paul Childress; Marta Alvarez; Edward F Srour; Angela Bruzzaniti; Louis M Pelus; Christie M Orschell; Melissa A Kacena
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

9.  Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation.

Authors:  Wendy A Ciovacco; Ying-Hua Cheng; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

10.  Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation.

Authors:  Justin M Lemieux; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-04-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.